nach oben

Erschienen in:

01.03.2016 | Original Paper

Pathological α-synuclein distribution in subjects with coincident Alzheimer’s and Lewy body pathology

verfasst von: Jon B. Toledo, Pallavi Gopal, Kevin Raible, David J. Irwin, Johannes Brettschneider, Samantha Sedor, Kayla Waits, Susana Boluda, Murray Grossman, Vivianna M. Van Deerlin, Edward B. Lee, Steven E. Arnold, John E. Duda, Howard Hurtig, Virginia M.-Y. Lee, Charles H. Adler, Thomas G. Beach, John Q. Trojanowski

Erschienen in: Acta Neuropathologica | Ausgabe 3/2016

Einloggen, um Zugang zu erhalten

Abstract

We investigated the distribution patterns of Lewy body-related pathology (LRP) and the effect of coincident Alzheimer disease (AD) pathology using a data-driven clustering approach that identified groups with different LRP pathology distributions without any diagnostic or researcher’s input in two cohorts including: Parkinson disease patients without (PD, n = 141) and with AD (PD-AD, n = 80), dementia with Lewy bodies subjects without AD (DLB, n = 13) and demented subjects with AD and LRP pathology (Dem-AD-LB, n = 308). The Dem-AD-LB group presented two LRP patterns, olfactory-amygdala and limbic LRP with negligible brainstem pathology, that were absent in the PD groups, which are not currently included in the DLB staging system and lacked extracranial LRP as opposed to the PD group. The Dem-AD-LB individuals showed relative preservation of substantia nigra cells and dopamine active transporter in putamen. PD cases with AD pathology showed increased LRP. The cluster with occipital LRP was associated with non-AD type dementia clinical diagnosis in the Dem-AD-LB group and a faster progression to dementia in the PD groups. We found that (1) LRP pathology in Dem-AD-LB shows a distribution that differs from PD, without significant brainstem or extracranial LRP in initial phases; (2) coincident AD pathology is associated with increased LRP in PD indicating an interaction; (3) LRP and coincident AD pathology independently predict progression to dementia in PD, and (4) evaluation of LRP needs to acknowledge different LRP spreading patterns and evaluate substantia nigra integrity in the neuropathological assessment and consider the implications of neuropathological heterogeneity for clinical and biomarker characterization.

Nur mit Berechtigung zugänglich

Aarsland D, Ballard CG, Halliday G (2004) Are Parkinson’s disease with dementia and dementia with Lewy bodies the same entity? J Geriatr Psychiatry Neurol 17(3):137–145. doi:10.1177/0891988704267470 CrossRefPubMed

Beach TG, Adler CH, Lue L, Sue LI, Bachalakuri J, Henry-Watson J et al (2009) Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction. Acta Neuropathol 117(6):613–634. doi:10.1007/s00401-009-0538-8 PubMedCentralCrossRefPubMed

Beach TG, Adler CH, Sue LI, Serrano G, Shill HA, Walker DG et al (2015) Arizona study of aging and neurodegenerative disorders and brain and body donation program. Neuropathology 35(4):354–389. doi:10.1111/neup.12189 PubMedCentralCrossRefPubMed

Beach TG, Sue LI, Walker DG, Roher AE, Lue L, Vedders L et al (2008) the sun health research institute brain donation program: description and experience, 1987–2007. Cell Tissue Bank 9(3):229–245. doi:10.1007/s10561-008-9067-2 PubMedCentralCrossRefPubMed

Berg D, Postuma RB, Bloem B, Chan P, Dubois B, Gasser T et al (2014) Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson’s disease. Mov Disord 29(4):454–462. doi:10.1002/mds.25844 PubMedCentralCrossRefPubMed

Bohnen NI, Muller ML, Kotagal V, Koeppe RA, Kilbourn MA, Albin RL et al (2010) Olfactory dysfunction, central cholinergic integrity and cognitive impairment in Parkinson’s disease. Brain 133(Pt 6):1747–1754. doi:10.1093/brain/awq079 PubMedCentralCrossRefPubMed

Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K (2006) Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 112(4):389–404. doi:10.1007/s00401-006-0127-z PubMedCentralCrossRefPubMed

Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82(4):239–259CrossRefPubMed

Braak H, Del Tredici K (2008) Invited article: nervous system pathology in sporadic Parkinson disease. Neurology 70(20):1916–1925. doi:10.1212/01.wnl.0000312279.49272.9f CrossRefPubMed

10.

Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24(2):197–211 (pii: S0197458002000659) CrossRefPubMed

11.

Braak H, Ghebremedhin E, Rub U, Bratzke H, Del Tredici K (2004) Stages in the development of Parkinson’s disease-related pathology. Cell Tissue Res 318(1):121–134. doi:10.1007/s00441-004-0956-9 CrossRefPubMed

12.

Clavaguera F, Bolmont T, Crowther RA, Abramowski D, Frank S, Probst A et al (2009) Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol 11(7):909–913. doi:10.1038/ncb1901 PubMedCentralCrossRefPubMed

13.

Consensus recommendations for the postmortem diagnosis of Alzheimer’s disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer’s Disease (1997). Neurobiol Aging 18 (4 Suppl):S1-2

14.

Del Tredici K, Braak H (2012) Spinal cord lesions in sporadic Parkinson’s disease. Acta Neuropathol 124(5):643–664. doi:10.1007/s00401-012-1028-y CrossRefPubMed

15.

Dickson DW, Braak H, Duda JE, Duyckaerts C, Gasser T, Halliday GM et al (2009) Neuropathological assessment of Parkinson’s disease: refining the diagnostic criteria. Lancet Neurol 8(12):1150–1157CrossRefPubMed

16.

Dickson DW, Fujishiro H, Orr C, DelleDonne A, Josephs KA, Frigerio R et al (2009) Neuropathology of non-motor features of Parkinson disease. Parkinsonism Relat Disord 15(Suppl 3):S1–S5. doi:10.1016/S1353-8020(09)70769-2 CrossRefPubMed

17.

Dickson DW, Uchikado H, Fujishiro H, Tsuboi Y (2010) Evidence in favor of braak staging of Parkinson’s disease. Mov Disord 25(Suppl 1):S78–S82. doi:10.1002/mds.22637 CrossRefPubMed

18.

Emre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, Mizuno Y et al (2007) Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Mov Disord 22(12):1689–1707. doi:10.1002/mds.21507 (quiz 1837) CrossRefPubMed

19.

Giasson BI, Forman MS, Higuchi M, Golbe LI, Graves CL, Kotzbauer PT et al (2003) Initiation and synergistic fibrillization of tau and alpha-synuclein. Science 300(5619):636–640. doi:10.1126/science.1082324 CrossRefPubMed

20.

Goetz C, Emre M, Dubois B (2008) Parkinson’s disease dementia: definitions, guidelines, and research perspectives in diagnosis. Ann Neurol 64(S2):S81–S92CrossRefPubMed

21.

Graff-Radford J, Murray ME, Lowe VJ, Boeve BF, Ferman TJ, Przybelski SA et al (2014) Dementia with Lewy bodies: basis of cingulate island sign. Neurology 83(9):801–809. doi:10.1212/WNL.0000000000000734 PubMedCentralCrossRefPubMed

22.

Guo JL, Covell DJ, Daniels JP, Iba M, Stieber A, Zhang B et al (2013) Distinct alpha-synuclein strains differentially promote tau Inclusions in neurons. Cell 154(1):103–117. doi:10.1016/j.cell.2013.05.057 CrossRefPubMed

23.

Hawkes CH, Del Tredici K, Braak H (2010) A timeline for Parkinson’s disease. Parkinsonism Relat Disord 16(2):79–84. doi:10.1016/j.parkreldis.2009.08.007 CrossRefPubMed

24.

Heilbronner G, Eisele YS, Langer F, Kaeser SA, Novotny R, Nagarathinam A et al (2013) Seeded strain-like transmission of beta-amyloid morphotypes in APP transgenic mice. EMBO Rep 14(11):1017–1022. doi:10.1038/embor.2013.137 PubMedCentralCrossRefPubMed

25.

Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosur Psychiatry 55:181–184. doi:10.1136/jnnp.55.3.181 CrossRef

26.

Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC et al (2012) National institute on aging-Alzheimer’s association guidelines for the neuropathologic assessment of Alzheimer’s disease. Alzheimers Dement 8(1):1–13. doi:10.1016/j.jalz.2011.10.007 PubMedCentralCrossRefPubMed

27.

Hyman BT, Trojanowski JQ (1997) Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease. J Neuropathol Exp Neurol 56(10):1095–1097CrossRefPubMed

28.

Irwin DJ, White MT, Toledo JB, Xie SX, Robinson JL, Van Deerlin V et al (2012) Neuropathologic substrates of Parkinson disease dementia. Ann Neurol 72(4):587–598. doi:10.1002/ana.23659 PubMedCentralCrossRefPubMed

29.

Jellinger KA (2009) A critical evaluation of current staging of alpha-synuclein pathology in Lewy body disorders. Biochim Biophys Acta 1792(7):730–740. doi:10.1016/j.bbadis.2008.07.006 CrossRefPubMed

30.

Kalaitzakis ME, Graeber MB, Gentleman SM, Pearce RK (2008) Controversies over the staging of alpha-synuclein pathology in Parkinson’s disease. Acta Neuropathol 116(1):125–128. doi:10.1007/s00401-008-0381-3 (author reply 129–131) CrossRefPubMed

31.

Leverenz JB, Hamilton R, Tsuang DW, Schantz A, Vavrek D, Larson EB et al (2008) Empiric refinement of the pathologic assessment of Lewy-related pathology in the dementia patient. Brain Pathol 18(2):220–224. doi:10.1111/j.1750-3639.2007.00117.x PubMedCentralCrossRefPubMed

32.

Lippa CF, Duda JE, Grossman M, Hurtig HI, Aarsland D, Boeve BF et al (2007) DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology 68(11):812–819. doi:10.1212/01.wnl.0000256715.13907.d3 CrossRefPubMed

33.

Lu JX, Qiang W, Yau WM, Schwieters CD, Meredith SC, Tycko R (2013) Molecular structure of beta-amyloid fibrils in Alzheimer’s disease brain tissue. Cell 154(6):1257–1268. doi:10.1016/j.cell.2013.08.035 CrossRefPubMed

34.

McKeith IG, Dickson DW, Lowe J, Emre M, O’Brien JT, Feldman H et al (2005) Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65(12):1863–1872. doi:10.1212/01.wnl.0000187889.17253.b1 CrossRefPubMed

35.

Mirra SS (1997) The CERAD neuropathology protocol and consensus recommendations for the postmortem diagnosis of Alzheimer’s disease: a commentary. Neurobiol Aging 18(4 Suppl):S91–S94CrossRefPubMed

36.

Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW et al (2012) National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach. Acta Neuropathol 123(1):1–11. doi:10.1007/s00401-011-0910-3 PubMedCentralCrossRefPubMed

37.

Olichney JM, Murphy C, Hofstetter CR, Foster K, Hansen LA, Thal LJ et al (2005) Anosmia is very common in the Lewy body variant of Alzheimer’s disease. J Neurol Neurosurg Psychiatry 76(10):1342–1347. doi:10.1136/jnnp.2003.032003 PubMedCentralCrossRefPubMed

38.

Parkkinen L, Pirttila T, Alafuzoff I (2008) Applicability of current staging/categorization of alpha-synuclein pathology and their clinical relevance. Acta Neuropathol 115(4):399–407. doi:10.1007/s00401-008-0346-6 PubMedCentralCrossRefPubMed

39.

Sanders DW, Kaufman SK, DeVos SL, Sharma AM, Mirbaha H, Li A et al (2014) Distinct tau prion strains propagate in cells and mice and define different tauopathies. Neuron. doi:10.1016/j.neuron.2014.04.047 PubMedCentralPubMed

40.

Sumikura H, Takao M, Hatsuta H, Ito S, Nakano Y, Uchino A et al (2015) Distribution of alpha-synuclein in the spinal cord and dorsal root ganglia in an autopsy cohort of elderly persons. Acta Neuropathol Commun 3:57. doi:10.1186/s40478-015-0236-9 PubMedCentralCrossRefPubMed

41.

Thal DR, Rub U, Orantes M, Braak H (2002) Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 58(12):1791–1800CrossRefPubMed

42.

Toledo JB, Brettschneider J, Grossman M, Arnold SE, Hu WT, Xie SX et al (2012) CSF biomarkers cutoffs: the importance of coincident neuropathological diseases. Acta Neuropathol 124(1):23–35. doi:10.1007/s00401-012-0983-7 PubMedCentralCrossRefPubMed

43.

Toledo JB, Cairns NJ, Da X, Chen K, Carter D, Fleisher A et al (2013) Clinical and multimodal biomarker correlates of ADNI neuropathological findings. Acta Neuropathol Commun 1(1):65. doi:10.1186/2051-5960-1-65 PubMedCentralCrossRefPubMed

44.

Toledo JB, Van Deerlin VM, Lee EB, Suh E, Baek Y, Robinson JL et al (2014) A platform for discovery: the university of pennsylvania integrated neurodegenerative disease biobank. Alzheimers dement 10(4):477–484. doi:10.1016/j.jalz.2013.06.003 (e471) PubMedCentralCrossRefPubMed

45.

Tsuboi Y, Dickson DW (2005) Dementia with Lewy bodies and Parkinson’s disease with dementia: are they different? Parkinsonism Relat Disord 11(Suppl 1):S47–S51. doi:10.1016/j.parkreldis.2004.10.014 CrossRefPubMed

46.

Wilson RS, Arnold SE, Schneider JA, Boyle PA, Buchman AS, Bennett DA (2009) Olfactory impairment in presymptomatic Alzheimer’s disease. Ann N Y Acad Sci 1170:730–735. doi:10.1111/j.1749-6632.2009.04013.x PubMedCentralCrossRefPubMed

47.

Zaccai J, Brayne C, McKeith I, Matthews F, Ince PG (2008) Patterns and stages of alpha-synucleinopathy: relevance in a population-based cohort. Neurology 70(13):1042–1048. doi:10.1212/01.wnl.0000306697.48738.b6 CrossRefPubMed

Titel: Pathological α-synuclein distribution in subjects with coincident Alzheimer’s and Lewy body pathology
verfasst von: Jon B. Toledo
Pallavi Gopal
Kevin Raible
David J. Irwin
Johannes Brettschneider
Samantha Sedor
Kayla Waits
Susana Boluda
Murray Grossman
Vivianna M. Van Deerlin
Edward B. Lee
Steven E. Arnold
John E. Duda
Howard Hurtig
Virginia M.-Y. Lee
Charles H. Adler
Thomas G. Beach
John Q. Trojanowski
Publikationsdatum: 01.03.2016
Verlag: Springer Berlin Heidelberg
Erschienen in: Acta Neuropathologica / Ausgabe 3/2016
Print ISSN: 0001-6322
Elektronische ISSN: 1432-0533
DOI: https://doi.org/10.1007/s00401-015-1526-9

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Was nützt die Kraniektomie bei schwerer tiefer Hirnblutung?

17.05.2024 Hirnblutung Nachrichten

Eine Studie zum Nutzen der druckentlastenden Kraniektomie nach schwerer tiefer supratentorieller Hirnblutung deutet einen Nutzen der Operation an. Für überlebende Patienten ist das dennoch nur eine bedingt gute Nachricht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Schwindelursache: Massagepistole lässt Otholiten tanzen

14.05.2024 Benigner Lagerungsschwindel Nachrichten

Wenn jüngere Menschen über ständig rezidivierenden Lagerungsschwindel klagen, könnte eine Massagepistole der Auslöser sein. In JAMA Otolaryngology warnt ein Team vor der Anwendung hochpotenter Geräte im Bereich des Nackens.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2016

Resident microglia rather than peripheral macrophages promote vascularization in brain tumors and are source of alternative pro-angiogenic factors

Presymptomatic activation of the PDGF-CC pathway accelerates onset of ALS neurodegeneration

Astrocytes: a central element in neurological diseases

Aberrant association of misfolded SOD1 with Na+/K+ATPase-α3 impairs its activity and contributes to motor neuron vulnerability in ALS

Microglia–blood vessel interactions: a double-edged sword in brain pathologies